Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
Since July 22nd 2016 - this date being 4 months after DB took over as CEO of Genedrive the shares price has fallen 50%. Back then TB, HCV and DoD were all heralded as the break through for this company. nearly 5 years later and none of these have delivered any material commercial revenue yet. AIHL has newly arrived and is also on the brink of sales - but will come too late to prevent a dilutive share issue, which will have to happen if no covid sales appear very soon. We've even had a global pandemic (in case anyone was unaware) and a 'gold standard' test and still no sales. I've invested in here for many years with varying size of investment and my current holding is still just about in profit. Its a disappointing whimper of an ending for me but its time for me to move on! Good luck to those that remain.
I hope DB is focused on Covid as there isnt enough cash coming in from anywhere else if not and he has spent a chunk of what remains on stock piling materials for beads.
DB showed AIHL in the recent presentation as ramping sales in the 6 - 12 month timeframe so all in line in the announcement......frustrating though as vaccine data review proves it can be done on a much quicker basis when there is a will tpo do it
yep. exactly. 1 share for every ten. Exciting times for Deepverge. Think you might do quite well with your holding DavieG9
@DavieG9. you are now the proud owner of Deepverge shares (the entity name for combo of Modern Water and integumen). As acceptances of the merger are above 90% there will be a compulsory conversion of your modern water shares into deepverge shares which i think should all wash through by Dec 2nd. Market makers still obviously taking orders here on MDW but the huge spread reflects their unwillingness to do much business here now. Focus on deepverge price now.
Many thanks kd82!
Agreed. can anyone clarify on this? Is this part of the final data evaluation DB mentioned in the recent investor call that would allow GDR and BC to start selling Sars Cov 2 test in the US without FDA EUA?
Have tried to get responses from IR at GEEC with very mixed success over the last few years. Recently sent email to ask for more information on the statement from the company about 'market reports' of GAIL pipeline to Kolkata going live in Feb got no reply. Would appreciate if any others on this board are able to get any response from IR on this issue.....or have any views on this. Thanks
"in the very very near future"
I heard him say a few more weeks to collect data and then assess where they are with FDA EUA. Implication is if FDA still taking time then they will press ahead without EUA. Few weeks away either way.
Sounds like AIHL will be a rapidly scaling market in the US over the next few months as well
Great post Technick! Couldn't agree more
Only one shareholder (other the than Modi family) with a holding large enough to be selling in this quantity and that is M&G. Maybe forced seller but i think they have been properly played by Modi family here. Modi's know that there is no buyer for such a large block of stock so let shares drift down to mid single digits when they step in an buy the lot. They are probably the only buyer around of that size and so i wouldnt be surprised to see an RNS for their increased % holding and M&G's RNS for their decreased % holding. Pure speculation on my part though. Great to get this weight of selling out the way.
Just sharing an interesting article on risks around novel vaccine technology. Rushing through safety trials on a completely novel approach sits uneasily for most people. The article highlights the political imperative versus safety trade off that we are seeing here. Politics probably wins out so i'm not trying to suggest that vaccines are not going to be a feature of the landscape in 2021 but reading this only serves to highlight the lunacy of lowering safety requirements on a technology that hijacks the infrastructure of the human immune response. This is just one source of vaccine tech solution of course so just sharing for interest rather than linking to any bull or bear case for testing stocks.
https://www.zerohedge.com/medical/everything-you-dont-want-know-about-covid-vaccines-because-you-cant-be-bullish-anymore
Agreed, welcome back Ctw! its been a while. Assumed you had taken your millions off the table at £3 earlier this year. (maybe you did and are back in after this share price slump?)
market maker willing to take over 100,000 shares at 8p so a reasonable buyer in the background which is good. Not sure there are many willing to sell at the price though. I'm definitely not!
Lots of comment around covid stocks terminal outlook on here since Pfizer's announcement so lets just clarify some things as we stand. First up, i own GDR, have done for years and dont consider myself a 'ramper'. Bit of confirmatory bias creeps in every now and again...as it does with all of us.
Second, if you're reading this and new to investing or dont know much about genedrive then DONT BUY THIS STOCK. Scraps of private investor money flowing in isnt going to make any difference to the share price anyway.
Third, the current market cap leaves very little in for Covid related sales or any other sales. Some comments on here that GDR might get some sales away though so lets build on that assumption. Assume 5m tests sold and that company makes £3 in net cash per test sold - thats £15m cash in the bank. There is also another £8m or so cash raised earlier this year. Thats £23m in total. Add in the £9m of market cap that GDR traded on before the Covid broke out. Thats £32 market cap. Ie not much different to where they are now. There are a whole host of reasons why GDR are better placed now across their core business than they were back in Feb - AiHL and HCV WHO approval to name the 2 significant ones
Fourth, If we have learned one thing from this crisis it is (and this is a desperately sad fact) that most governments havent got a clue how to execute quickly on a mass nationwide healthcare response. There is no hope in hell that they will suddenly have worked out how to deliver a vast global vaccination programme in the next few months. Just look at the mess they've made on pretty much everything covid to date.
Fifth, i'm like most on here that we would all welcome a fast track back to a world where covid was not an issue anymore. I welcome the prospect of vaccines and better therapeutics and testing to deliver some kind of normality. But vaccines and vaccine approvals is now pretty much a totally separate issue to GDR's share price. Its priced in and more. Other factors may sink GDR from here but it wont be more vaccine news. But im not ramping so i repeat - DONT BUY THIS STOCK if you dont know what your buying into.
Understand the frustration from many here. remember though that the company are inviting questions for their presentation session next week. I've submitted some around demonstrating pathways to commercialisation in concrete tangible terms and encourage investors to do the same. They have to answer these questions and so we all need to be asking them.
https://www.investormeetcompany.com/
agreed Hasiba. Although it only takes 1 seller looking to offload a few 10s of thousands and the share price collapses. Buyers can afford to hold off for now and let sellers implode the share price. Not sure though what is going on with the 50% bid/offer spread. market makers seem to be killing off any chance of anyone wanting to place a trade.
Time for management to step in and buy a lot of stock here to send a clear signal of confidence in the outlook!
This was a tough half with severe lockdown restrictions curtailing business activity and demand. Company still managed to generate positive cashflow and keep shrinking net debt position. In reality there will most likely be no widely available vaccine in India through 2021 so things will continue to be tough but if they are still generating cash as it looks they will be then i'm happy.
Company allude to 'market reports' of GAIL pipleline to Kolkata being operational in Feb 2021. If accurate then this is really great news. Huge market there and GEEC can look forward to selling everything it produces soon
Investors generally seem to have swung into recovery mode and looking for value in equity markets. This is a deep value opportunity. Unfortunately too illiquid for many institutional investors.
Nothing about shale gas permissions or timetable for test wells and nothing about a timeframe for main market listing in London, both of which would be good to hear about. All in though this is a good update. Looking forward to 2021!
Just listened to the presentation from David Wilson - Commercial Director at Avacta. He stated several times that every test would be needed in the UK and that 5m tests a day would be expected to return the UK back to some kind of normal and normal economic activity. 'Market can accommodate multiple and all test manufacturers' and 'everything that is produced will be sold and quickly'. He was also at pains to say that UK government now see home grown diagnostic companies as strategic national assets not just for this pandemic but also for the next one and that support to build this capability in the UK is a priority and will continue after Covid 19 crisis subsides.
Bound to talk his own company up and its prospects so pinch of salt required but highly supportive comments for GDR. PCR important but wont be able to do it alone and POC needed to facilitate the rapid and huge scale-up in testing volumes needed. If you think the GDR technology is no good then GDR will obviously struggle not just with Covid but also across other markets. If you think the technology is good then this is a strategic national asset selling for £60m. (can someone explain to me though how lateral flow technology links to GDR POC if at all?)
Several have stated already on this board and i fully agree that the bigger strategic picture is about partnerships, leading technology and scale. The pieces take a little time to get in place but we are nearly there now. The world has changed and diagnostics have the floor. Diagnostics is an industry that has represented only around 0.6% of European total healthcare expenditure. All governments have realised that effective and rapidly responsive healthcare of the future will need this figure to be much much higher. Dump GDR because of some short-term share price volatility and lack of a weekly RNS if you want but i think that would be a mistake. Just my view. DYOR as always (and maybe listen to this presentation on playback)
Looks like a few buyers nibbling again. not surprised at near £10m mkt cap. If we can keep the seller away for a while this might drift up nearer to £20 valuation. Hopefully the interim results will throw a bit of light on current trading and underlying profit in the new covid environment, pipeline to Kolkata issues, shale permits, and main london listing plans. Patience needed, but looks like a very good time to get in for the patient investor